Blue Horseshoe Stocks: Weekly Wrap-Up

Pharma Options Recap

We cast a wide net yesterday with a trio of options ideas in the pharma space related to the reversal of the Trump administration’s position on drug rebate policy. The sector was bustling with activity in the premarket, and two out of our three ideas bore fruit.

Here were the total possible gains available to daytraders for the session:

Cigna Corp. CI $167.50-175 Calls 

$167.50 Calls – Range: 10.04-17.00 – Max Gain: 52%
$170 Calls – Range: 10.02-14.30 – Max Gain: 58%
$175 Calls – Range: 1.10-1.80 – Max Gain: 64%
____

United Health Corp. UNH $250-255 Calls 

$250 Calls – Range: 2.48-11.09 – Max Gain: 52%
$252.50 Calls – Range: 2.50-8.70 – Max Gain: 58%
$255 Calls – Range: .99-6.20 – Max Gain: 70%

In addition to these plays, we’ll continue to keep an eye on the CVS Health Corp. CVS Weekly $57-58.50 Calls  through the end of the day.
____

Fresh Idea:
SPDR S&P500 (ETF) SPY $299-300 Calls


Taronis Technologies, Inc. TRNX

On Monday morning, we highlighted TRNX as a prime bottom-bounce candidate, and we’d like to wrap up the week by going over the solid swings which we subsequently observed in the stock.

On Monday itself, our choice in timing on calling this play was affirmed as we saw a solid 52% run from  .25-.38. This was followed by a pullback to a low of .1832 the following day, and over the course of the rest of the week, TRNX has stair-stepped its way back up to .34, which represents an additional 86% swing.


Extended Watchlist:
MLNT, CLVS, NVCN, APLS, SFIX, ADXS, INFY, OBLN

Blue Horseshoe Stocks: EXCLUSIVE AMPG INTERVIEW

AmpliTech Group, Inc. AMPG

We’ve been keeping track of AMPG for ten weeks now, and not only did the stock make a run from .043 to .084 during that time, but it has managed to hold more than half of those gains upon consolidation, and has held firm in the .065-.075 area.

For a company that, for the time being, is rather small in size, AmpliTech has serviced some big accounts in both the government and private sectors. The company’s RF signal amplifiers are top of the line in terms of noise reduction effectiveness, and AMPG exhibited its wares at a recent high profile conference.

We were pleased to attend the 2019 International Microwave Symposium in Boston, Massachusetts last week, where we got the opportunity to sit down and conduct a face-to-face interview with Fawad Maqbool, the CEO of AmpliTech. We highly recommend that you take a few moments to check it out.


VIEW AMPG INTERVIEW NOW!


RH, Inc. RH – Recap

Our bearish options trading idea from yesterday’s report turned out to be our bigger winner for the day. We selected the  RH Weekly $120-118 Puts even after the company posted a solid beat on Q1 earnings and raised guidance.

It might have seemed like a counter-intuitive choice to some, but we had good reason. The stock was gapping up way too high in the premarket. We predicted that it would fall after the open, and it turned out to be the right hunch.

The following intraday gains were made possible by our idea:

RH Weekly $120-118 Puts
$120 Puts: 3.80-8.40 (+121%)
$119 Puts: 3.90-6.75 (+73%)
$118 Puts: 3.00-6.29 (+110%)

____

Fresh Options Idea:
AVGO Weekly $252.50-257.50 Calls

Important: DO NOT attempt to trade options contracts with a weekly expiration on a Friday unless you are an advanced level trader with access to disposable funds.


Extended Watchlist:
NVCN, NAKD, HUSA, ARQL, KURA, IGC, LGCY, FVPR

Blue Horseshoe Stocks: PIRS Review & More

Pieris Pharmaceuticals Inc. PIRS – Review

Of all the types of plays we search for, bottom watch plays can require the most amount of patience as compared to other quick-strike ideas that we formulate. We highlighted PIRS as such back in mid-February, and over the past quarter, the stock has produced some very favorable results in two distinct runs.

When we initially signaled our interest in this stock, or shortly thereafter, it was trading for as little as 2.83 and over the course of the next two months, it gradually made its way to 4.00 (+41%). After a pullback down near its original level at 2.81 halfway through last month, the stock has begun to run once again. This time it has reached all new highs, with the stock changing hands for as much as 4.68/share on Friday. That second push allowed us to see an overall increase of 67%

We wouldn’t be at all surprised to have to come back to PIRS once again in the near future. In addition to the company’s joint clinical venture with pharma super giant AstraZeneca, the stock itself has recently received analyst upgrades that could just be the beginning of PIRS’s next leg-up.


Xalles Holdings, Inc. XALL

We are also looking at the incredible momentum recently built up by XALL, which has been assisted by the resurgence of Bitcoin here in 2019, which began in January in the mid-$3000 range, and has persisted to the present time to the current highs near $8700.

The company also recently decreased its public float by around 50%, making it that much easier for the stock to move. We’ll be interested to continue to monitor its progress, especially if the latest Bitcoin boom continues to persist as it has in recent months.


Extended Watchlist:
DRRX, CBLK, BLNK, CTRV, MOSY, SNSS, NVCN, ATVI, LAHO(>>News Alert)